FDA: Anti-smoking drugs Chantix, Zyban need mental health warnings

07/1/2009 | Google

The FDA ordered warnings of mental health risks on the labels of Pfizer's Chantix and GlaxoSmithKline's Zyban in light of reports linking the smoking-cessation drugs to behavioral changes, depression, hostility and suicidal thoughts. Pfizer said it has already made the risk information available to health care providers and patients by updating Chantix's label in accordance with FDA guidelines.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Tarrytown, NY
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI